Opinion|Videos|December 6, 2023
Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.
Advertisement
Episodes in this series
Advertisement
Related to this article
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5